Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    11-July-2000      
Issue 89 Next Update - 14:00 UTC 08:00 EST    12-July-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Proceed To Article Interleukin-2 (IL-2) As Immune-Based Therapy For HIV
An important article in the July 12 issue of the Journal of the American Medical Association (JAMA) by Dr. Richard T. Davey, Jr., of the National Institute of Allergy and Infectious Diseases (NIAID) and colleagues heralds a series of anticipated papers and presentations over the coming months. All will report new data on the potential role of interleukin-2 (IL-2) in treating people with HIV infection. An immune-based therapy, IL-2 is a laboratory-engineered product modeled after a substance the body makes that promotes T-cell growth. More...

Proceed To Article IL-2 Information At The NIH
Clinicians interested in the clinical trials regarding Interleukin-2 can use this list of links to a variety of sites at the NIH to study the trials in greater detail. Most of the trials are concluded and their summaries are posted in this list. The Interleukin-2 and HIV trials will be in the news in the coming months as information from the world-wide AIDS conference in South Africa is released. More...

Proceed To Article Interleukin-2 Information For Patients
Newly released clinical trials involving the use of IL-2 in HIV infected patients will increase the demand for information on the drug. Vidyya presents this fact sheet on IL-2 for the use of your patients. More...
Proceed To Article Nationwide Recall Of Sangcya Oral Solution
The Food and Drug Administration today announced the nationwide recall of SangCya oral solution, a generic version of the anti-rejection drug cyclosporine (Neoral oral solution), because of clinical evidence that the generic drug's availability is reduced relative to Neoral oral solution if the drug is administered with apple juice. Patients taking cyclosporine capsules are not affected by this recall. More...

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.